Imophoron

Bristol, United Kingdom Founded: 2017 • Age: 9 yrs
CDMO focused on manufacturing of vaccines
Annual revenue - Latest available
Total funding $1.0M 2 rounds
Employees 11 Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Imophoron

Imophoron is a company based in Bristol (United Kingdom) founded in 2017. Imophoron has raised $1.01 million across 2 funding rounds. The company has 11 employees as of December 31, 2023. Imophoron operates in a competitive market with competitors including Neovacs, Intravacc, Fina Biosolutions, Yapanbio and VERAXA, among others.

  • Headquarter Bristol, United Kingdom
  • Employees 11 as on 31 Dec, 2023
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Imophoron Limited
  • Date of Incorporation 05 Dec, 2017
  • Jurisdiction BRISTOL, ENGLAND
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $1.01 M (USD)

    in 2 rounds

  • Latest Funding Round
    $506.76 K (USD), Seed

    Jun 14, 2023

  • Investors
    Not available
  • Employee Count
    11

    as on Dec 31, 2023

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Imophoron

Headcount 1-10
Employee Profiles 2
Employee Profiles
People
Frédéric Garzoni
Co-founder, Cso, Director

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Imophoron

Imophoron has successfully raised a total of $1.01M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $506.76 thousand completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investments & Acquisitions by Imophoron

Investments
Premium access

Investment portfolio details for Imophoron

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Imophoron

Premium access

Detailed financials for Imophoron

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Imophoron Comparisons

Imophoron Primary company
Description
CDMO focused on manufacturing of vaccines
Location
Bristol, United Kingdom
Founded Year
2017
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
11
As of 2023
Premium access

Peer comparison for Imophoron

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Imophoron

Imophoron operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neovacs, Intravacc, Fina Biosolutions, Yapanbio and VERAXA, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Vaccine manufacturing services are provided by Neovacs CDMO.
Locked Locked Locked
Vaccine development services for bacterial and viral vaccines are provided.
Locked Locked Locked
Biotechnology company specializing in bioconjugation services mainly for vaccine development
Locked Locked Locked
Contract manufacturing of bio-therapeutics and vaccines is provided.
Locked Locked Locked
Antibody therapeutics for cancer treatment are developed via microfluidic screening.
Locked Locked Locked
New molecules are discovered, developed, and manufactured in biotechnology.
Premium access

Detailed competitors of Imophoron

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Imophoron

Premium access

Complete news archive for Imophoron

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Imophoron

Imophoron was founded in 2017 and raised its 1st funding round 6 years after it was founded.

Imophoron is headquartered in Bristol, United Kingdom. It is registered at Bristol, England, United Kingdom.

Imophoron is a funded company, having raised a total of $1.01M across 2 funding rounds to date.

As of Dec 31, 2023, the latest employee count at Imophoron is 11.

Imophoron was founded in 2017 in Bristol, United Kingdom, operating as a contract development and manufacturing organization in the biotechnology sector. Vaccine production services are provided for diseases including respiratory syncytial virus, COVID, and Chikungunya. A specialized platform is developed to address existing infectious threats and potential future pathogens, supporting global health needs through targeted manufacturing capabilities.

Imophoron's top competitors include Neovacs, Yapanbio and VERAXA.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available